In vitro bactericidal activity of 0.6% povidone-iodine eye drops formulation

2018 ◽  
Vol 29 (6) ◽  
pp. 673-677 ◽  
Author(s):  
Rosario Musumeci ◽  
Francesco Bandello ◽  
Marianna Martinelli ◽  
Enrico Calaresu ◽  
Clementina Elvezia Cocuzza
Keyword(s):  
Staphylococcus Aureus ◽  
Bactericidal Activity ◽  
Staphylococcus Epidermidis ◽  
Povidone Iodine ◽  
Bacterial Load ◽  
Eye Drops ◽  
Ophthalmic Surgery ◽  
Free Iodine

Purpose:To evaluate the bactericidal activity of a diluted povidone-iodine formulation (0.6%) in comparison with the most used 5% povidone-iodine solution ophthalmic preparation.Methods:In vitro bactericidal activity comparison between 0.6% povidone-iodine versus 5% povidone-iodine formulations, against these bacteria: Staphylococcus aureus ATCC 25923, Staphylococcus aureus ATCC 43300, Staphylococcus epidermidis ATCC 12228, linezolid-resistant Staphylococcus epidermidis α99 strain, a clinical isolate, Pseudomonas aeruginosa ATCC 27853, Escherichia coli ATCC 25922.Results:About 0.6% povidone-iodine formulation was demonstrated to be faster than 5% povidone-iodine preparation in killing Gram-positive as well as Gram-negative bacteria. Against a linezolid-resistant methicillin-resistant Staphylococcus epidermidis strain, 0.6% povidone-iodine formulation showed the best antiseptic efficacy requirement of 3-log10reduction in bacterial load, if compared with the 5% povidone-iodine formulation.Conclusion:Our investigation has demonstrated that the more diluted 0.6% preparation was more rapidly bactericidal than the 5% povidone-iodine formulation, most probably due to the fact that dilution from 5% to 0.6% increases the amount of free iodine. While our finding must be confirmed by in vivo clinical studies, this fact constitutes an intriguing news for what concerns the use of povidone-iodine eye drops in the ocular surface treatment before intravitreal injections as well as ophthalmic surgery.

scholarly journals Anaerobic Conditions Induce Expression of Polysaccharide Intercellular Adhesin in Staphylococcus aureus and Staphylococcus epidermidis

2001 ◽  
Vol 69 (6) ◽  
pp. 4079-4085 ◽  
Author(s):  
Sarah E. Cramton ◽  
Martina Ulrich ◽  
Friedrich Götz ◽  
Gerd Döring
Keyword(s):  
Staphylococcus Aureus ◽  
Staphylococcus Epidermidis ◽  
Biofilm Formation ◽  
Extracellular Polysaccharide ◽  
Growth Conditions ◽  
Anaerobic Conditions ◽  
Anaerobic Environment ◽  
Specific Mrna

ABSTRACT Products of the intercellular adhesion (ica) operon in Staphylococcus aureus and Staphylococcus epidermidis synthesize a linear β-1,6-linked glucosaminylglycan. This extracellular polysaccharide mediates bacterial cell-cell adhesion and is required for biofilm formation, which is thought to increase the virulence of both pathogens in association with prosthetic biomedical implants. The environmental signal(s) that triggers ica gene product and polysaccharide expression is unknown. Here we demonstrate that anaerobic in vitro growth conditions lead to increased polysaccharide expression in both S. aureus and S. epidermidis, although the regulation is less stringent inS. epidermidis. Anaerobiosis also dramatically stimulates ica-specific mRNA expression inica- and polysaccharide-positive strains of both S. aureus and S. epidermidis.These data suggest a mechanism whereby ica gene expression and polysaccharide production may act as a virulence factor in an anaerobic environment in vivo.

scholarly journals Comparative Efficacies of Human Simulated Exposures of Telavancin and Vancomycin against Methicillin-Resistant Staphylococcus aureus with a Range of Vancomycin MICs in a Murine Pneumonia Model

2010 ◽  
Vol 54 (12) ◽  
pp. 5115-5119 ◽  
Author(s):  
Jared L. Crandon ◽  
Joseph L. Kuti ◽  
David P. Nicolau
Keyword(s):  
Staphylococcus Aureus ◽  
Bacterial Load ◽  
Infection Model ◽  
Time Curve ◽  
Unbound Fraction ◽  
Methicillin Resistant ◽  
Vancomycin Mics ◽  
Mrsa Strains

ABSTRACT Telavancin displays potent in vitro and in vivo activity against methicillin-resistant Staphylococcus aureus (MRSA), including strains with reduced susceptibility to vancomycin. We compared the efficacies of telavancin and vancomycin against MRSA strains with vancomycin MICs of ≥1 μg/ml in a neutropenic murine lung infection model. Thirteen clinical MRSA isolates (7 vancomycin-susceptible, 2 vancomycin-heteroresistant [hVISA], and 4 vancomycin-intermediate [VISA] isolates) were tested after 24 h, and 7 isolates (1 hVISA and 4 VISA isolates) were tested after 48 h of exposure. Mice were administered subcutaneous doses of telavancin at 40 mg/kg of body weight every 12 h (q12h) or of vancomycin at 110 mg/kg q12h; doses were designed to simulate the area under the concentration-time curve for the free, unbound fraction of drug (fAUC) observed for humans given telavancin at 10 mg/kg q24h or vancomycin at 1 g q12h. Efficacy was expressed as the 24- or 48-h change in lung bacterial density from pretreatment counts. At dose initiation, the mean bacterial load was 6.16 ± 0.26 log10 CFU/ml, which increased by averages of 1.26 ± 0.55 and 1.74 ± 0.68 log in untreated mice after 24 and 48 h, respectively. At both time points, similar CFU reductions were noted for telavancin and vancomycin against MRSA, with vancomycin MICs of ≤2 μg/ml. Both drugs were similarly efficacious after 24 and 48 h of treatment against the hVISA strains tested. Against VISA isolates, telavancin reduced bacterial burdens significantly more than vancomycin for 1 of 4 isolates after 24 h and for 3 of 4 isolates after 48 h. These data support the potential utility of telavancin for the treatment of MRSA pneumonia caused by pathogens with reduced susceptibility to vancomycin.

scholarly journals Oral Administration of the Broad-Spectrum Antibiofilm Compound Toremifene Inhibits Candida albicans and Staphylococcus aureus Biofilm FormationIn Vivo

2014 ◽  
Vol 58 (12) ◽  
pp. 7606-7610 ◽  
Author(s):  
Kaat De Cremer ◽  
Nicolas Delattin ◽  
Katrijn De Brucker ◽  
Annelies Peeters ◽  
Soña Kucharíková ◽  
...  
Keyword(s):  
Staphylococcus Aureus ◽  
Candida Albicans ◽  
Broad Spectrum ◽  
Staphylococcus Epidermidis ◽  
Biofilm Formation ◽  
Candida Krusei ◽  
Content Type ◽  
And Staphylococcus Aureus

ABSTRACTWe here report on thein vitroactivity of toremifene to inhibit biofilm formation of different fungal and bacterial pathogens, includingCandida albicans,Candida glabrata,Candida dubliniensis,Candida krusei,Pseudomonas aeruginosa,Staphylococcus aureus, andStaphylococcus epidermidis. We validated thein vivoefficacy of orally administered toremifene againstC. albicans and S. aureusbiofilm formation in a rat subcutaneous catheter model. Combined, our results demonstrate the potential of toremifene as a broad-spectrum oral antibiofilm compound.

scholarly journals Establishing in vitro and in vivo Co-culture Models of Staphylococcus epidermidis and Enterococcus faecalis to Evaluate the Effect of Topical Fluoroquinolone on Ocular Microbes

2021 ◽  
Vol 8 ◽  
Author(s):  
Han Woo Kim ◽  
Jiyeun Kate Kim ◽  
Indal Park ◽  
Sang Joon Lee
Keyword(s):  
Enterococcus Faecalis ◽  
Staphylococcus Epidermidis ◽  
Ocular Surface ◽  
Eye Drops ◽  
Culture Model ◽  
Color Detection ◽  
Culture Models

Purpose: To establish in vitro and in vivo ocular co-culture models of Staphylococcus epidermidis and Enterococcus faecalis and to study how various concentrations of moxifloxacin affect the survival of these two endophthalmitis-causing bacteria.Methods: Standard strains of S. epidermidis and E. faecalis were used. Color detection agar plates were employed to distinguish their colonies. To establish the in vitro and in vivo co-culture models, S. epidermidis and E. faecalis were co-cultivated at different ratios for various periods. For the in vivo model, various volumes and concentrations of either a mono-culture or co-culture were inoculated into the lower conjunctival sac of rabbits. Finally, the newly developed in vitro and in vivo co-culture models were subjected to the moxifloxacin treatment to access its effect on S. epidermidis and E. faecalis.Results: When S. epidermidis and E. faecalis were cultured separately in tryptic soy broth, their growth peaked and plateaued at approximately 16 and 6 h, respectively. When they were co-cultured, the growth peak of S. epidermidis got delayed, whereas the growth peak of E. faecalis did not change. The number of E. faecalis was significantly higher in the co-culture than that in the mono-culture. Treatment with moxifloxacin in the in vitro co-culture model rapidly decreased the number of S. epidermidis cells at doses ≥ 0.125 μg/ml. In contrast, the number of E. faecalis did not change significantly up to 16 μg/ml moxifloxacin. In in vivo co-culture (at 1:1), the S. epidermidis count decreased in a pattern similar to that seen in in vivo mono-culture and was barely detectable at 24 h after inoculation. In contrast, the of E. faecalis count increased up to 16 h and then decreased. When moxifloxacin was applied (zero, one, or two times) to this model, the S. epidermidis count decreased in proportion to the number of treatments. In contrast, the E. faecalis count increased with moxifloxacin treatment.Conclusions: The in vitro and in vivo co-culture models of S. epidermidis and E. faecalis were established to determine the influence of moxifloxacin eye drops on these bacteria. The results clearly show that the moxifloxacin eye drops can make E. faecalis dominant on the ocular surface.

scholarly journals Impact of Inoculum Size and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) on Vancomycin Activity and Emergence of VISA in an In Vitro Pharmacodynamic Model

2008 ◽  
Vol 53 (2) ◽  
pp. 805-807 ◽  
Author(s):  
Warren E. Rose ◽  
Steven N. Leonard ◽  
Kerri L. Rossi ◽  
Glenn W. Kaatz ◽  
Michael J. Rybak
Keyword(s):  
Staphylococcus Aureus ◽  
Bactericidal Activity ◽  
Bacterial Load ◽  
Inoculum Size ◽  
Pharmacodynamic Model ◽  
High Inoculum ◽  
High Bacterial Load

ABSTRACT The activity of vancomycin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and non-hVISA isolates, using an in vitro pharmacodynamic model, was reduced in the presence of a high inoculum amount (108 CFU/ml). A high bacterial load of >105 CFU/ml persisted for all strains with doses up to 5 g every 12 h against high inoculum amounts. No change in the vancomycin MIC was detected in any isolate at a moderate inoculum amount (106 CFU/ml), and bactericidal activity occurred only against the non-hVISA isolate (time to 99% kill, 7.5 h; P = 0.001).

scholarly journals Determinación de la cinética, pruebas de crecimiento y efecto de inhibición in vitro de Lactobacillus casei en Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus agalactiae y Escherichia coli

2015 ◽  
Vol 62 (2) ◽  
Author(s):  
Henry Jurado-Gámez ◽  
Manuel Gúzman-Insuasty
Keyword(s):  
Escherichia Coli ◽  
Staphylococcus Aureus ◽  
Streptococcus Agalactiae ◽  
Staphylococcus Epidermidis ◽  
Lactobacillus Casei ◽  
E Coli

<p>Se determinó la cinética, pruebas de crecimiento y el efecto de inhibición <em>in vitro</em> de <em>Lactobacillus casei</em> sobre <em>Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus agalactiae </em>y<em> Escherichia coli</em>. Se usaron cepas de casa comercial y cepas aisladas en la Vereda La Victoria, Corregimiento de Catambuco al suroccidente del municipio de Pasto, Nariño, Colombia. Se evaluó el efecto de los antibióticos Dicloxacilina, Cefepima, Cefalotina, Ciprofloxacina, Gentamicina, Penicilina, Trimetropim Sulfa y Ampicilina. Se evaluó la inhibición producida por <em>L. casei</em> y su sobrenadante sobre las bacterias patógenas. El crecimiento de la bacteria láctica se evaluó con tres niveles de pH (2,5, 4,5 y 7),  tres concentraciones de sales biliares (0,5, 1 y 2%) y dos de bilis bovina (1 y 1,2%), y dos temperaturas (38 y 45°C). Igualmente se determinó la cinética de crecimiento y las variables pH, azúcar total, proteína y ácido láctico.  Mediante HPLC se determinaron los péptidos y los ácidos orgánicos presentes en el sobrenadante. <em>L. casei </em>mostró susceptibilidad a la Ciprofloxacina y Ampicilina, mientras que <em>S. aureus </em>mostró susceptibilidad y resistencia a todos los antibióticos para la cepa comercial y aislada respectivamente, el mismo comportamiento se presentó con <em>S. epidermidis</em>. Las cepas de <em>S. agalactiae</em> y <em>E. coli</em> aisladas y comerciales mostraron susceptibilidad a los antibióticos.  La cepa láctica mostró un efecto de inhibición de <em>S. aureus</em>, <em>S. epidermidis</em> y  <em>S. agalactiae</em>, pero no fue efectiva con <em>E. coli</em>, igual comportamiento se observó con el uso del sobrenadante de la bacteria láctica. Se encontró crecimiento de 1 x 10<sup>10</sup> y 5,1 x 10<sup>7</sup> UFC/ml para 1 y 1,2 % de bilis bovina; 2,3 x 10<sup>7</sup>, 1 x 10<sup>9</sup> y 3 x 10<sup>8</sup> UFC/ml para 0,5, 1 y 2 % de sales biliares respectivamente; 1,1 x 10<sup>11</sup>, 2,0 x 10<sup>10</sup> y 1,0 x 10<sup>10</sup> UFC/ml para  pH de 2,5, 4,5 y 7 respectivamente. La fase exponencial se encontró a 16:48 horas con un crecimiento de 3 x 10<sup>10</sup> UFC/ml. La variables pH, azúcar, acidez y proteína durante la fase exponencial fueron de 4,94, 0,88 mg/l, 2,89 mg/l y 1,9 mg/l, respectivamente. La prueba de HPLC para péptidos mostró la presencia de una cadena VAL-TIR-VAL y para ácidos orgánicos se encontró una producción de 83,46% de ácido láctico. <em>L. casei </em> mostró buenas características probiótica que permitirían su aplicación en ensayos in vivo para el control de microorganismos causantes de mastitis subclínica en vacas.</p>

scholarly journals Efficacy of the New Lantibiotic NAI-107 in Experimental Infections Induced by Multidrug-Resistant Gram-Positive Pathogens

2011 ◽  
Vol 55 (4) ◽  
pp. 1671-1676 ◽  
Author(s):  
Daniela Jabés ◽  
Cristina Brunati ◽  
GianPaolo Candiani ◽  
Simona Riva ◽  
Gabriella Romanó ◽  
...  
Keyword(s):  
Bactericidal Activity ◽  
Bacterial Load ◽  
Severe Infection ◽  
Multidrug Resistant ◽  
Minimal Bactericidal Concentration ◽  
Gram Positive ◽  
Immunocompetent Mice ◽  
Dose Proportional

ABSTRACTNAI-107 is a novel lantibiotic active against Gram-positive bacteria, including methicillin-resistantStaphylococcus aureus(MRSA), glycopeptide-intermediateS. aureus(GISA), and vancomycin-resistant enterococci (VRE). The aim of this study was to evaluate thein vivoefficacy of NAI-107 in animal models of severe infection. In acute lethal infections induced with a penicillin-intermediateStreptococcus pneumoniaestrain in immunocompetent mice, or with MRSA, GISA, and VRE strains in neutropenic mice, the 50% effective dose (ED50) values of NAI-107 were comparable or lower than those of reference compounds, irrespective of the strain and immune status (0.51 to 14.2 mg/kg of body weight for intravenous [i.v.] NAI-107, 5.1 to 22.4 for oral linezolid, and 22.4 for subcutaneous [s.c.] vancomycin). Inthe granuloma pouch model induced in rats with a MRSA strain, intravenous NAI-107 showed a dose-proportional bactericidal activity that, at a single 40-mg/kg dose, compared with 2 20-mg/kg doses at a 12-h or 24-h interval, caused a 3-log10-CFU/ml reduction of viable MRSA in exudates that persisted for more than 72 h. Rat endocarditis was induced with a MRSA strain and treated for five consecutive days. In a first experiment, using 5, 10, or 20 mg/kg/day, and in a second experiment, when 10 mg/kg at 12-h intervals was compared to 20 mg/kg/day, intravenous NAI-107 was effective in reducing the bacterial load in heart vegetations in a dose-proportional manner. Trough plasma levels, as determined on days 2 and 5, were several times higher than the NAI-107 minimal bactericidal concentration (MBC). NAI-107 binding to rat and human serum ranges between 93% and 98.6%. The rapid bactericidal activity of NAI-107 observedin vitrowas thus confirmed by the efficacy in several models of experimental infection induced by Gram-positive pathogens, supporting further investigation of the compound.

scholarly journals In Vitro and In Vivo Efficacies of Teicoplanin-Loaded Calcium Sulfate for Treatment of Chronic Methicillin-Resistant Staphylococcus aureus Osteomyelitis

2009 ◽  
Vol 54 (1) ◽  
pp. 170-176 ◽  
Author(s):  
Wei-Tao Jia ◽  
Shi-Hua Luo ◽  
Chang-Qing Zhang ◽  
Jian-Qiang Wang
Keyword(s):  
Staphylococcus Aureus ◽  
Antibacterial Activity ◽  
Calcium Sulfate ◽  
Release Kinetics ◽  
Bacterial Load ◽  
Rabbit Model ◽  
Methicillin Resistant ◽  
Group 2

ABSTRACT The i n vitro and in vivo therapeutic efficacies of teicoplanin-loaded calcium sulfate (TCS; 10% [wt] teicoplanin) were investigated in a rabbit model of chronic methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis. The in vitro elution characteristics of teicoplanin from TCS pellets were realized by carrying out an evaluation of the release kinetics, recovery rate, and antibacterial activity of the released teicoplanin. Chronic osteomyelitis was induced by inoculating 107 CFU of a MRSA strain into the tibial cavity of rabbits. After 3 weeks, the animals were treated by debridement followed by implantation of TCS pellets in group 1, calcium sulfate (CS) pellets alone in group 2, and intravenous (i.v.) teicoplanin (6 mg/kg of body weight every 12 h for three doses and then every 24 h up to 4 weeks) in group 3. Animals in group 4 were left untreated. After 6 weeks, the efficacy of the osteomyelitis treatment was evaluated by hematological, radiological, microbiological, and histological examinations. In vitro elution studies showed sustained release of teicoplanin at a therapeutic level over a time period of 3 weeks. The released teicoplanin maintained its antibacterial activity. In vivo, the best therapeutic effect was observed in animals treated with TCS pellets, resulting in significantly lower radiological and histological scores, lower positive rates of MRSA culture and bacterial load, and excellent bone regeneration compared with those treated by CS alone or i.v. teicoplanin, without any local or systemic adverse effects. TCS pellets are an effective alternative to i.v. teicoplanin for the treatment of chronic MRSA osteomyelitis, particularly because teicoplanin is delivered locally while the TCS pellets simultaneously promote bone defect repair.

Sign in / Sign up

Export Citation Format

Share Document